NCT07197645View on ClinicalTrials.gov

Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

April 26, 2027

Study Completion Date

July 5, 2027

Conditions
Bone PainMetastatic Bone TumorBone Metastases in Subjects With Advanced Cancer
Interventions
DRUG

153Sm-DOTMP

TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that exhibits avid uptake as shown by 99mTcdiphosphonate bone scans undertaken within 60 days of dosing.

All Listed Sponsors
lead

Telix Pharmaceuticals (Innovations) Pty Limited

INDUSTRY